John J. Acton
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Chemical Synthesis and Analysis, Peroxisome Proliferator-Activated Receptors, Parkinson's Disease Mechanisms and Treatments, Computational Drug Discovery Methods, Neuropeptides and Animal Physiology
Most-Cited Works
- → Benzoyl 2-methyl indoles as selective PPARγ modulators(2004)131 cited
- → Selective PPARγ modulators with improved pharmacological profiles(2005)62 cited
- → (±)- Trans -2-(3-methoxy-5-methylsulfonyl-4-propoxyphenyl)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran (L-659,989), a novel, potent PAF receptor antagonist(1988)58 cited
- → Amitriptyline produces analgesia in the formalin pain test(1992)53 cited
- → Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic Acid (MK-0533): A Novel Selective Peroxisome Proliferator-Activated Receptor γ Modulator for the Treatment of Type 2 Diabetes Mellitus with a Reduced Potential to Increase Plasma and Extracellular Fluid Volume(2009)52 cited
- → Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors(2021)40 cited
- → Design of potent and selective GPR119 agonists for type II diabetes(2010)31 cited
- → Development, synthesis, and biological evaluation of (-)-trans-(2S,5S)-2-[3-[(2-oxopropyl)sulfonyl]-4-n-propoxy-5-(3-hydroxypropoxy)-phenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran, a potent orally active platelet-activating factor (PAF) antagonist and its water-soluble prodrug phosphate ester(1992)29 cited
- → Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1 H -Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease(2022)20 cited
- → Synthesis and biological activity of MK 287 (L-680,573): a potent, specific and orally active paf receptor antagonist(1991)19 cited